No Data
No Data
No Data
No Data
No Data
荃信生物-B:2023年度報告
Futu NewsApr 26 07:01 ET · Announcements
[Monthly IPO Report] The Hong Kong stock IPO market is the starting force, Fujing China Holdings overbought more than 293 times, and Hongji Group made a maximum profit of 4,800 yuan in the first sale
After February's silence, the Hong Kong stock IPO market exploded in March. Seven companies went public one after another, and only 1 went bankrupt. Source: Jinwu Financial News March Fund-raising King - Although the number of listed companies has clearly picked up, it still lacks the boost of large companies. Judging from the scale of fund-raising, the 7 new shares introduced in March were small in overall size, and the Miko Group, which raised the highest amount of capital, was only HK$918 million. According to reports, the company is the third-largest potash enterprise in China and has market advantages. However, industry growth is expected to be in the low single digits. The market for the company's main product, potassium chloride, is also relatively concentrated, and development needs to face challenges. Sino-Thai International said earlier that the government
金吾財訊Apr 3 05:28 ET
QYUNS-B: FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
Futu NewsMar 28 04:41 ET · Announcements
Changes in Hong Kong stocks | Quanxin Bio-B (02509) rose by more than 14%. The company is deeply involved in the self-exempt circuit, and the QX001S is expected to become the first commercial product
The Zhitong Finance App learned that Quanxin Biotech B (02509) rose by more than 14%. As of press release, it had risen 12.06% to HK$20.35, with a turnover of HK$318.66. According to reports, Quanxin Biotech is a clinical-stage biotechnology company focusing on the development of biotherapies for autoimmune and allergic diseases. The company's core competitiveness is its two core products, QX002N and QX005N, which are independently developed. QX002N is an IL-17A inhibitor. The company has conducted phase III clinical trials for the treatment of ankylosing spondylitis (AS) in China. QX005N is a resistor
Zhitong FinanceMar 26 02:53 ET
Hong Kong Shares Inch Up After China Holds Benchmark Rates Steady; Qyuns Therapeutics Falls 9% on Debut
Hong Kong shares finished fractionally higher on Wednesday on encouraging corporate results, with traders keeping a watchful eye on the future direction of the People's Bank of China's monetary policy
MT NewswiresMar 20 04:41 ET
[IPO] Quanxin Biotech (02509) closed at HK$24.5, 23.74% higher than the offering price
Jinwu Financial News | Quanxin Biotech (02509) closed at HK$24.5, 23.74% higher than the offering price. It traded 2,308,200 shares throughout the day, with a turnover of HK$61.6727 million. Excluding handling fees, each lot earns HK$940 for 200 shares. The stock opened at HK$27.4 in early trading, which was 38.38% higher than the offering price. The daily high was HK$28.2, and the lowest price was HK$24.5. The latest total market value is HK$5.441 billion.
金吾財訊Mar 20 04:23 ET
No Data
No Data